Skip to main content

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

Asthma

Investigators Dr. Donald Cockcroft and Dr. Beth Davis from the Department of Medicine - Division of Respirology, Critical Care and Sleep Medicine at the University of Saskatchewan are inviting those between the ages of 18 and 65 who have been diagnosed with allergic asthma to participate in this clinical research study.

Tiotropium (Spiriva Respimat®) is a medication used to treat respiratory conditions. The purpose of this study is to investigate the protective effects of tiotropium on the response to allergen exposure in individuals with mild allergic asthma.

For more information about this study, including study design, eligibility criteria, procedures, and time commitment, please review the participant information and consent form link below.

To participate in this study, email investigator Dr. Beth Davis with your interest at beth.davis@usask.ca or call 306 844 1444.

Participant Information and Consent Form Link